Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt. JAG ACCEPTERAR CORPORATE FINANCE ISSUER SERVICES CERTIFIED ADVISER EVENTS ABOUT US News Equity Research Careers Contact Vator Securities Nordic Tech Day Summit The Nordic Tech Day Summit was held on November 16th and was a digital investor event where you got the opportunity to meet some of the most interesting and innovative companies in Nordic tech. 1 2 3 4 5 Corporate Finance Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders. READ MORE About Us Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele. READ MORE On November 16th, Vator Securities arranged the Vator Securities Nordic Tech Day Summit, a digital investor event where you got the opportunity to meet some of the most interesting and innovative companies in Nordic tech. The participating companies were Precise Biometrics, Proact IT Group, Sivers Semiconductors, Rebelle, InCoax, Waystream, Pharem Biotech, mResell, Awardit, JonDeTech and Epulse. Watch the presentations from the event Vator Securities advises Precise Biometrics on 23 MSEK Directed Share Issue 30 November 2021 Precise Biometrics is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics. Precise intends to use the net proceeds from the directed issue to finance part of the company’s acquisition of EastCoast Solutions. read more Vator Securities advises SenzaGen on 30 MSEK Directed Share Issue 29 October 2021 SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings read more Unleashing a paradigm shift in early detection of pancreatic cancer 24 September 2021 Advancing into commercial phase, Immunovia has achieved a strong launch of its first product IMMray PanCan-d which was shortly followed by backing of the largest US patient organization Pancreatic Cancer Action Network (PanCAN) and the US National Pancreas Foundation (NPF). Such support provides real-world commercial third-party validation and should reinforce the capital market’s confidence in the test’s performance and clinical utility offer. read more Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue 7 September 2021 Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 67,6 million. Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase. read more MORE NEWS 30 MSEK | Q2 2021 23 MSEK | Q4 2021 ALL TRANSACTIONS 1 2 3 4 5 Legal documents (Swedish) Legal information om Vator Securities Allmänna villkor för handel med finansiella instrument Riktlinjer för hantering av personuppgifter Risker avseende finansiella instrument Information om klagomål Ersättningspolicy Redogörelse ersättningar 2020 Riktlinjer för bästa möjliga resultat Avgiftsstruktur Information om kundkategorisering Information om kundkommunikation Periodisk information om kapitaltäckning och likviditetsrisker, 2021 Q2 Information om Pelare 3, 2020 Vator Securities Kungsgatan 34, 7tr 111 35 Stockholm +46 8 5333 2737 info@vatorsec.se LinkedIn Youtube